7,8-Dibromo-9-methyl-2-(piperazin-1-yl)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline monohydrochloride

Catalog No. :
ACCIXL428
CAS No. :
2443816-41-7
Molecular Formula :
C15H19Br2ClN4
Molecular Weight :
450.61

IUPAC Name:7,8-dibromo-9-methyl-2-(piperazin-1-yl)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline hydrochloride

7,8-Dibromo-9-methyl-2-(piperazin-1-yl)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline monohydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5mg98%$120.00Login to see priceIn stockInquiry
10mg98%$179.00Login to see priceIn stockInquiry
25mg98%$322.00Login to see priceIn stockInquiry
50mg98%$508.00Login to see priceIn stockInquiry
100mg98%$812.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7,8-Dibromo-9-methyl-2-(piperazin-1-yl)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline monohydrochloride
IUPAC Name7,8-dibromo-9-methyl-2-(piperazin-1-yl)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline hydrochloride
Molecular FormulaC15H19Br2ClN4
Molecular Weight450.61
SMILESCC1=C2C3=C(C(Br)=C1Br)CCCN3C(N4CCNCC4)=N2.[H]Cl
InChI KeyGQXLWUCQESKBSC-UHFFFAOYSA-N
Synonym4H-Imidazo[4,5,1-ij]quinoline, 7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-, hydrochloride (1:1);Romaciclib monohydrochloride;OD0030
CAS No.2443816-41-7

Synthetic Route by SureRoute

1. ACCIXL428 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUMO414 route compound structure diagram
    ACEUMO41459813-05-7
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCIXL428 route product structure diagram
    ACCIXL4282443816-41-7 In Stock
Inquiry

2. ACCIXL428 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACCIXL428 route product structure diagram
    ACCIXL4282443816-41-7 In Stock
Inquiry

Comments (0)